MedTrace Logo

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

NCT02687711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 544

Last updated 2021-08-04

Study results available
· View outcomes & findings →

Summary

Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.

Conditions

  • Epilepsy With POS With or Without Secondary Generalization

Sponsors & Collaborators

  • Pharm Research Associates Ltd. UK

    collaborator INDUSTRY

  • UCB Biopharma S.P.R.L.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · +1 844 599 2273 (UCB)

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Denmark
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687711 on ClinicalTrials.gov